New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures The research assesses how protocol design ...
This article is part of our series on clinical data considerations. Read How to Approach Fundraising and Investor Relations. When it comes to disclosing clinical trial data in the biotechnology arena, ...
Clinical Ink, a pharma-focused mobile clinical trial data collection company, has raised $4.3 million. FCA Venture partners led the round, with additional funding from 10 undisclosed angel investors.
A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...
“End-to-End” Strategies Achieve Better Enrollment, Diversity, and Data Collection in Clinical Trials
The revolution in cancer drug development has a caveat: Only a fraction of eligible patients take part in clinical trials. Historically, findings from studies estimate that the share of eligible ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results